TICKERNOMICS Sign up
Last Update: 2024-03-28 02:15:12
PURPLE BIOTECH LTD. ( PPBT ) https://purple-biotech.com
0.62USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
Israel
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
-64.67%
PPBT
SPY
32.74%
-85.23%
PPBT
SPY
92.93%
-48.18%
PPBT
SPY
224.41%
PPBT
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
13.58
12.60
0.06
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.66
23.01
0.35
-137.02
0.00
-0.59
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
562.86
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
16.3552
-74.73
-53.08
3.24
Other Earnings and Cash Flow Stats:
PURPLE BIOTECH LTD. ( PPBT ) Net Income TTM ($MM) is -19.96
PURPLE BIOTECH LTD. ( PPBT ) Operating Income TTM ($MM) is -22.55
PURPLE BIOTECH LTD. ( PPBT ) Owners' Earnings Annual ($MM) is -19.16
PURPLE BIOTECH LTD. ( PPBT ) Current Price to Owners' Earnings ratio is -0.71
PURPLE BIOTECH LTD. ( PPBT ) EBITDA TTM ($MM) is -21.56
PURPLE BIOTECH LTD. ( PPBT ) EBITDA Margin is 0.00%
Capital Allocation:
PURPLE BIOTECH LTD. ( PPBT ) has paid 0.00 dividends per share and bought back -3.755367 million shares in the past 12 months
PURPLE BIOTECH LTD. ( PPBT ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
PURPLE BIOTECH LTD. ( PPBT ) Interest-bearing Debt ($MM) as of last quarter is 0
PURPLE BIOTECH LTD. ( PPBT ) Annual Working Capital Investments ($MM) are -2
PURPLE BIOTECH LTD. ( PPBT ) Book Value ($MM) as of last quarter is 38
PURPLE BIOTECH LTD. ( PPBT ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
PURPLE BIOTECH LTD. ( PPBT ) has 15 million in cash on hand as of last quarter
PURPLE BIOTECH LTD. ( PPBT ) has 6 million of liabilities due within 12 months, and long term debt 0 as of last quarter
PURPLE BIOTECH LTD. ( PPBT ) has 21 common shares outstanding as of last quarter
PURPLE BIOTECH LTD. ( PPBT ) has 0 million USD of preferred stock value
Academic Scores:
PURPLE BIOTECH LTD. ( PPBT ) Altman Z-Score is -4.17 as of last quarter
PURPLE BIOTECH LTD. ( PPBT ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
PURPLE BIOTECH LTD. ( PPBT ) largest shareholder is owning shares at 0.00 ($MM) value
(an insider) shares of PURPLE BIOTECH LTD. ( PPBT ) for the amount of $ on
4.29% of PURPLE BIOTECH LTD. ( PPBT ) is held by insiders, and 1.00% is held by institutions
PURPLE BIOTECH LTD. ( PPBT ) went public on 2015-11-20
Other PURPLE BIOTECH LTD. ( PPBT ) financial metrics:
FCF:-17.57
Unlevered Free Cash Flow:-20.64
EPS:-0.92
Operating Margin:562.86
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-52.19
Beta:3.24
Buffet's Owners Earnings:-19.16
Price to Owner's Earnings:-0.71
About PURPLE BIOTECH LTD. ( PPBT ) :
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of tranion, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company for the Phase 2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy; and Mor Research Applications. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.